Dimerix, a biopharmaceutical company specialising in inflammatory diseases, commenced adolescent patient recruitment for its ACTION3 Phase 3 global clinical trial in patients with focal segmental glomerulosclerosis.

The Independent Data Monitoring Committee confirmed that the dose of DMX-200 to be used in adolescent patients aged 12-17 years is the same 120mg dose currently administered to adult participants.

"The positive recommendation of the IDMC to allow adolescent dosing further extends the strong safety profile and tolerability of DMX-200 when used in FSGS patients," said David Fuller, chief medical officer at Dimerix.

The ACTION3 Phase 3 study aims to evaluate the efficacy and safety of DMX-200 in patients with FSGS, a leading cause of kidney failure in children.